Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy

AIDS

Volumn 27, Issue 4, 2013, Pages 529-538

  Egaña Gorroño, Lander ^a   Martínez, Esteban ^b   Cormand, Bru ^c   Escribà, Tuixent ^a   Gatell, Jose ^b   Arnedo, Mireia ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital Clinic   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antiretroviral therapy; dyslipidemia; genetics; HIV

Indexed keywords

ABC TRANSPORTER A1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; HAPLOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FASTING; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATITIS C; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; LIPIDS; MALE; MIDDLE AGED; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN; TRIGLYCERIDES;

EID: 84873413710     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835d0da1     Document Type: Article

References (30)

1. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
2. Manuel O, Thiebaut R, Darioli R, Tarr PE. Treatment of dyslipidaemia in HIV-infected persons. Expert Opin Pharmacother 2005; 6:1619-1645.
3. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94:515-519.
4. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
5. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
6. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med 2010; 18:112-118.
7. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15:329-334.
8. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
9. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
10. Group DADS, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
11. Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, Martinez R, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419-1426.
12. Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007; 17:755-764.
13. Rotger M, Bayard C, Taffe P, Martinez R, Cavassini M, Bernasconi E, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet 2009; 2:621-628.
14. Tindall EA, Petersen DC, Nikolaysen S, Miller W, Schuster SC, Hayes VM. Interpretation of custom designed Illumina genotype cluster plots for targeted association studies and nextgeneration sequence validation. BMC Res Notes 2010; 3:39.
15. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9. low LDL. and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
16. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14:1066-1074.
17. Martinez E, Leyes P, Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS 2008; 3:240-246.
18. Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis- Taillard C, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46:761-767.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
20. Storey JD. A direct approach to false discovery rates. J Royal Stat Soc Series B 2002; 64 (Part 3):479-498.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
23. Dudbridge F. A survey of current software for linkage analysis. Hum Genomics 2003; 1:63-65.
24. Schork NJ, Nath SK, Fallin D, Chakravarti A. Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjects.AmJ Hum Genet 2000; 67:1208-1218.
25. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41:47-55.
26. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009; 41:35-46.
27. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
28. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological. clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707- 713.
29. O'Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol 2008; 61:299- 310.
30. Diong C, Raboud J, Li M, Cooper C, Ontario HIVTNCST. HIV/ hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia. HIV Med 2011; 12:403-411.